Advances in chalcones with anticancer activities

Recent Patents on Anti-Cancer Drug Discovery

Volumn 10, Issue 1, 2015, Pages 97-115

  Karthikeyan, Chandrabose ^a   Narayana Moorthy, Narayana S H ^a,b   Ramasamy, Sakthivel ^c   Vanam, Uma ^c   Manivannan, Elangovan ^d   Karunagaran, Devarajan ^c   Trivedi, Piyush ^a  

^a UNIVERSITY INSTITUTE OF TECHNOLOGY   (India)

^b UNIVERSITY OF PORTO   (Portugal)

^c INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

^d DEVI AHILYA UNIVERSITY   (India)

Author keywords

Anticancer; Anticancer chalcones; Antioxidant; Antiproliferative activity; Chalcones; Patents

Indexed keywords

1 FURAN 2 YL 3 PHENYL PROPENONE; 1,3 DIPHENYL PROPENONE; 2' HYDROXY 2,3,4',6' TETRAMETHOXYCHALCONE; 3 PHENYL 1 THIOPHEN 2 YL PROPENONE; 3 PHENYL 1 THIOPHEN 3 YL PROPENONE; 4 HYDROXYDERRICIN; BENZOTHIAZOLE; BROUSSOCHALCONE A; BUTEIN; CARDAMONIN; CHALCONE; DIMETHYLAMINOCHALCONE; EPHRIN RECEPTOR B2; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FLAVOKAWAIN A; FLAVOKAWAIN B; GARCINOL; HYDROXY SAFFLOR YELLOW A; IMIDAZOLE DERIVATIVE; LAVOKAWAIN C; LICOCHALCONE A; ORGANIC COMPOUND; PYRANOCHALCONE; PYRROL [2,1 C] [1,4] BENZODIAZEPINE; TIE 1 RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; XANTHOANGELOL; XANTHOHUMOL; ANTINEOPLASTIC AGENTS; CHALCONES;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; IC50; INTRACELLULAR SIGNALING; NEOPLASM; NONHUMAN; PATENT; PRIORITY JOURNAL; SUBSTITUTION REACTION; ANIMALS; CHEMISTRY; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CHALCONES; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS;

EID: 84920862323     PISSN: 15748928     EISSN: 22123970     Source Type: Journal    
DOI: 10.2174/1574892809666140819153902     Document Type: Article

References (107)

1. Orlikova B, Tasdemir D, Golais F, Dicato M, Diederich M. Dietary chalcones with chemopreventive and chemotherapeutic potential. Genes Nutr 2011; 6(2): 125-47
2. Srinivasan B, Johnson TE, Lad R, Xing C. Structure-activity relationship studies of chalcone leading to 3-hydroxy-4,3,4,5 tetramethoxychalcone and its analogues as potent nuclear factor B inhibitors and their anticancer activities. J Med Chem 2009; 52(22): 7228-35
3. Modzelewska A, Pettit C, Achanta G, Davidson NE, Huang P, Khan SR. Anticancer activities of novel chalcone and bis-chalcone derivatives. Bioorg Med Chem 2006; 14(10): 3491-5
4. Maria K, Dimitra HL, Maria G. Synthesis and anti-inflammatory activity of chalcones and related Mannich bases. Med Chem 2008; 4(6): 586-96
5. Wu J, Li J, Cai Y, Pan Y, Ye F, Zhang Y, et al. Evaluation and discovery of novel synthetic chalcone derivatives as antiinflammatory agents. J Med Chem 2011; 54(23): 8110-23
6. Nowakowska Z. A review of anti-infective and anti-inflammatory chalcones. Eur J Med Chem 2007; 42(2): 125-37
7. Miranda CL, Stevens JF, Ivanov V, McCall M, Frei B, Deinzer ML, et al. Antioxidant and prooxidant actions of prenylated and nonprenylated chalcones and flavanones in vitro. J Agric Food Chem 2000; 48(9): 3876-84
8. Chiaradia LD, Mascarello A, Purificação M, Vernal J, Cordeiro MNS, Zenteno ME, et al. Synthetic chalcones as efficient inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase PtpA. Bioorg Med Chem Lett 2008; 18(23): 6227-30
9. Wu JH, Wang XH, Yi YH, Lee KH. Anti-AIDS agents 54. A potent anti-HIV chalcone and flavonoids from genus Desmos. Bioorg Med Chem Lett 2003; 13(10): 1813-5
10. Domınguez JN, Charris JE, Lobo G, de Domınguez GN, Moreno MM, Riggione F, et al. Synthesis of quinolinylchalcones and evaluation of their antimalarial activity. Eur J Med Chem 2001; 36(6): 555-60
11. Dimmock JR, Elias DW, Beazely MA, Kandepu NM. Bioactivities of chalcones. Curr Med Chem 1999; 6(12): 1125-49
12. Batovska DI, Todorova IT. Trends in utilization of the pharmacological potential of chalcones. Curr Clin Pharmacol 2010; 5(1): 1-29
13. Sahu NK, Balbhadra SS, Choudhary J, Kohli DV. Exploring pharmacological significance of chalcone scaffold: A review. Curr Med Chem 2012; 19(2): 209-25
14. Iwamura C, Shinoda K, Yoshimura M, Watanabe Y, Obata A, Nakayama T. Naringeninchalcone suppresses allergic asthma by inhibiting the type-2 function of CD4 T cells. Allergol Int 2010; 59(1): 67-73
15. Go ML, Wu X, Liu XL. Chalcones: An update on cytotoxic and chemoprotective properties. Curr Med Chem 2005; 12(4): 481-99
16. Ducki S. Antimitotic chalcones and related compounds as inhibitors of tubulin assembly. Anticancer Agents Med Chem 2009; 9(3): 336-47
17. Zuo Y, Yu Y, Wang S, Shao W, Zhou B, Lin L, et al. Synthesis and cytotoxicity evaluation of biaryl-based chalcones and their potential in TNF induced nuclear factor-B activation inhibition. Eur J Med Chem 2012; 50: 393-404
18. Yang EB, Guo YJ, Zhang K, Chen YZ, Mack P. Inhibition of epidermal growth factor receptor tyrosine kinase by chalcone derivatives. Biochim Biophy Acta 2001; 1550(2): 144-52
19. Rizvi SU, Siddiqui HL, Nisar M, Khan N, Khan I. Discovery and molecular docking of quinolyl-thienylchalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase. Bioorg Med Chem Lett 2012; 22(2): 942-4
20. Li QS, Li CY, Lu X, Zhang H, Zhu HL. Design, synthesis and biological evaluation of novel (E)-alpha-benzylsulfonylchalcone derivatives as potential BRAF inhibitors. Eur J Med Chem 2012; 50: 288-95
21. Boumendjel A, Ronot X, Boutonnat J. Chalcones derivatives acting as cell cycle blockers: Potential anticancer drugs?. Curr Drug Targets 2009; 10(4): 363-71
22. Sharma V, Kumar V, Kumar P. Heterocyclic chalcone analogues as potential anticancer agents. Anticancer Agents Med Chem 2013; 13(3): 422-32
23. Zhang E-H, Wang R-F, Guo S-Z, Liu B. An update on antitumor activity of naturally occurring chalcones. Evidence-Based Compl Alternat Med 2013; 2013: 815621 (1-22)
24. Chimenti F, Fioravanti R, Bolasco A, Chimenti P, Secci D, Rossi F, et al. Chalcones: A valid scaffold for monoamine oxidases inhibitors. J Med Chem 2009; 52: 2818-24
25. Fu Y, Hsieh TC, Guo J, Kunicki J, Lee MYWT, Darzynkiewicz Z, et al. Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgenindependent PC-3 prostate cancer cells. Biochem Biophy Res Comm 2004; 322: 263-70
26. Chen M, Theander TG, Christensen SB, Hviid L, Zhai L, Kharazmil A. Licochalcone A, a new antimalarial agent, inhibits in vitro growth of the human malaria parasite Plasmodium falciparum and protects mice from P. yoelii infection. Antimicrob Agents Chemother 1994; 38: 1470-5
27. Lust S, Vanhoecke B, Janssens A, Philippe J, Bracke M, Offner F. Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism. Mol Nutr Food Res 2005; 49: 844-50
28. Pan L, Becker H, Gerhauser C. Xanthohumol induces apoptosis in cultured 40-16 human colon cancer cells by activation of the death receptor and mitochondrial pathway. Mol Nutr Food Res 2005; 49: 837-43
29. Tabata K, Motani K, Takayanagi N, Nishimura R, Asami S, Kimura Y, et al. Xanthoangelol, a major chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma and leukemia cells. Biol Pharm Bull 2005; 28(8): 1404-7
30. Akihisa T, Kikuchi T, Nagai H, Ishii K, Tabata K, Suzuki T. 4-Hydroxyderricin from Angelica keiskei roots induces caspasedependent apoptotic cell death in HL60 human leukemia cells. J Oleo Sci 2011; 60(2): 71-7
31. Yit CC, Das NP. Cytotoxic effect of butein on human colon adenocarcinoma cell proliferation. Cancer Lett 1994; 82: 65-72
32. Kim NY, Pae HO, Oh GS, Kang TH, Kim YC, Rhew HY, et al. Butein, a plant polyphenol, induces apoptosis concomitant with increased caspase-3 activity, decreased Bcl-2 expression and increased Bax expression in HL-60 cells. Pharmacol Toxicol 2001; 88: 261-6
33. Hong J, Sang S, Park HJ, Kwon SJ, Suh N, Huang MT, et al. Modulation of arachidonic acid metabolism and nitric oxidesynthesis by garcinol and its derivatives. Carcinogenesis 2006; 27: 278-86
34. Padhye S, Ahmad A, Oswal N, Sarkar FH. Emerging role of Garcinol, the antioxidant chalcone from Garcinia indica Choisy and its synthetic analogs. J Hematol Oncol 2009; 2: 38(1-13)
35. Zi X, Simoneau AR. Flavokawain A, a novel chalcone from kava extract induces apoptosis in bladded cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res 2005; 65: 3479-86
36. Xi S, Zhang Q, Xie H, Liu L, Liu C, Gao X, et al. Effects of hydroxysafflor yellow A on blood vessel and mRNA expression with VEGF and bFGF of transplantation tumor with gastric adenocarcinoma cell line BGC-823 in nude mice. ZhongguoZhong Yao ZaZhi 2009; 34: 605-10
37. Rao YK, Kao TY, Ko JL, Tzeng YM. Chalcone HTMC causes in vitro selective cytotoxicity, cell-cycle G1 phase arrest through p53-dependent pathway in human lung adenocarcinoma A549 cells, and in vivo tumor growth suppression. Bioorg Med Chem Lett 2010; 20(22): 6508-12
38. Ye H, Fu A, Wu W, Li Y, Wang G, Tang M, et al. Cytotoxic and apoptotic effects of constituents from Millettia pachycarpa Benth. Fitoterapia 2012; 83(8): 1402-8
39. Kong Y, Wang K, Edler MC, Hamel E, Mooberry SL, Paige MA, et al. A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent. Bioorg Med Chem 2010; 18: 971-7
40. Boumendjel A, Boccard J, Carrupt PA, Nicolle E, Blanc M, Geze A, et al. Antimitotic and antiproliferative activities of chalcones: Forward structure-activity relationship. J Med Chem 2008; 51: 2307-10
41. Tu HY, Huang AM, Hour TC, Yang SC, Pu YS, Lin CN. Synthesis and biological evaluation of 2',5'-dimethoxychalcone derivatives as microtubule-targeted anticancer agents. Bioorg Med Chem 2010; 18(6): 2089-98
42. Lorenzo P, Alvarez R, Ortiz MA, Alvarez S, Piedrafita FJ, de Lera AR. Inhibition of IkappaB kinase-beta and anticancer activities of novel chalcone adamantyl arotinoids. J Med Chem 2008; 51(17): 5431-40
43. Zhang H, Liu JJ, Sun J, Yang XH, Zhao TT, Lu X, et al. Design, synthesis and biological evaluation of novel chalcone derivatives as antitubulin agents. Bioorg Med Chem 2012; 20(10): 3212-8
44. Ducki S, Rennison D, Woo M, Kendall A, Chabert JF, McGown AT, et al. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivascular activity. Bioorg Med Chem 2009; 17: 7698-710
45. Ducki S, Mackenzie G, Greedy B, Armitage S, Chabert JF, Bennett E, et al. Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones. Bioorg Med Chem 2009; 17: 7711-22
46. Nakagawa-Goto K, Chen TH, Peng CY, Bastow KF, Wu JH, Lee KH. Antitumor agents 259. Design, syntheses, and structureactivity relationship study of desmosdumotin C analogs. J Med Chem 2007; 50(14): 3354-8
47. Sharma A, Chakravarti B, Gupt MP, Siddiqui JA, Konwar R, Tripathi RP. Synthesis and antibreast cancer activity of biphenyl based chalcones. Bioorg Med Chem 2010; 18(13): 4711-20
48. Shi HB, Zhang SJ, Ge QF, Guo DW, Cai CM, Hu WX. Synthesis and anticancer evaluation of thiazolyl-chalcones. Bioorg Med Chem Lett 2010; 20(22): 6555-9
49. Solomon VR, Lee H. Anti-breast cancer activity of heteroarylchalcone derivatives. Biomed Pharmacother 2012; 66(3): 213-20
50. de Vasconcelos A, Campos VF, Nedel F, Seixas FK, Dellagostin OA, Smith KR, et al. Cytotoxic and apoptotic effects of chalcone derivatives of 2-acetyl thiophene on human colon adenocarcinoma cells. Cell Biochem Funct 2013; 31(4): 289-97
51. Kumar D, Kumar NM, Akamatsu K, Kusaka E, Harada H, Ito T. Synthesis and biological evaluation of indolylchalcones as antitumor agents. Bioorg Med Chem Lett 2010; 20: 3916-9
52. Martel-Frachet V, Kadri M, Boumendjel A, Ronot X. Structural requirement of arylindolylpropenones as anti-bladder carcinoma cells agents. Bioorg Med Chem 2011; 19(20): 6143-8
53. Valdameri G, Gauthier C, Terreux R, Kachadourian R, Day BJ, Winnischofer SMB, et al. Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: Critical role of methoxylation in both inhibition potency and cytotoxicity. J Med Chem 2012; 55: 3193-200
54. Boumendjel A, McLeer-Florin A, Champelovier P, Allegro D, Muhammad D, Souard F, et al. A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in vitro and in vivo glioblastoma models. BMC Cancer 2009; 9: 242 (1-11)
55. Robinson MW, Overmeyer JH, Young AM, Erhardt PW, Maltese WA. Synthesis and evaluation of indole-based chalcones as inducers of methuosis, a novel type of nonapoptotic cell death. J Med Chem 2012; 55(5): 1940-56
56. Gurkan-Alp AS, Mumcuoglu M, Andac CA, Dayanc E, CetinAtalay R, Buyukbingol E. Synthesis, anticancer activities and molecular modeling studies of novel indole retinoid derivatives. Eur J Med Chem 2012; 58: 346-54
57. Karthikeyan C, Solomon VR, Lee H, Trivedi P. Design, synthesis and biological evaluation of some isatin-linked chalcones as novel anti-breast cancer agents: A molecular hybridization approach. Biomed Prevent Nutr 2013; 3: 325-30
58. Kamal A, Reddy JS, Ramaiah MJ, Dastagiri D, Bharathi EV, PremSagar MV, et al. Design, synthesis and biological evaluation of imidazopyridine/pyrimidine-chalcone derivatives as potential anticancer agents. MedChemComm 2010; 1(5): 355-60
59. Tseng CH, Chen YL, Hsu CY, Chen TC, Cheng CM, Tso HC, et al. Synthesis and anti-proliferative evaluation of 3-phenyl-quinolinylchalcone derivatives against non-small cell lung cancers and breast cancers. Eur J Med Chem 2013; 59: 274-82
60. Abonia R, Insuasty D, Castillo J, Insuasty B, Quiroga J, Nogueras M, et al. Synthesis of novel quinoline-2-one based chalcones of potential anti-tumor activity. Eur J Med Chem 2012; 57: 29-40
61. Mielcke TR, Mascarello A, Filippi-Chiela E, Zanin RF, Lenz G, Leal PC, et al. Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation. Eur J Med Chem 2012; 48(0): 255-64
62. Sashidhara KV, Kumar A, Kumar M, Sarkar J, Sinha S. Synthesis and in vitro evaluation of novel coumarin-chalcone hybrids as potential anticancer agents. Bioorg Med Chem Lett 2010; 20(24): 7205-11
63. Patel K, Karthikeyan C, Moorthy NSHN, Trivedi P. Synthesis and cytotoxicity evaluation of some coumarinyl chalcones. Lett Drug Des Discov 2011; 8(4): 308-11
64. Wang G, Wu W, Peng F, Cao D, Yang Z, Ma L, et al. Design, synthesis, and structure-activity relationship studies of novel millepachine derivatives as potent antiproliferative agents. Eur J Med Chem 2012; 54: 793-803
65. Murthy YL, Suhasini KP, Pathania AS, Bhushan S, Sastry NY. Synthesis, structure activity relationship and mode of action of 3-substituted phenyl-1-(2,2,8,8-tetramethyl-3,4,9,10-tetrahydro-2H,8H-pyrano[2,3-f]chromen-6-yl)-propenones as novel anticancer agents in human leukaemia HL-60 cells. Eur J Med Chem 2013; 62: 545-55
66. Cheng H, Zhang L, Liu Y, Chen S, Lu X, Zheng Z, et al. Design, synthesis and discovery of 5-hydroxyaurone derivatives as growth inhibitors against HUVEC and some cancer cell lines. Eur J Med Chem 2010; 45(12): 5950-7
67. Sim HM, Wu CP, Ambudkar SV, Go ML. In vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs. Biochem Pharmacol 2011; 82(11): 1562-71
68. Viegas-Junior C, Danuello A, da Silva Bolzani V, Barreiro EJ, Fraga CA. Molecular hybridization: A useful tool in the design of new drug prototypes. Curr Med Chem 2007; 14(17): 1829-52
69. Walsh JJ, Bell A. Hybrid drugs for malaria. Curr Pharm Des 2009; 15: 2970-85
70. Anand N, Singh P, Sharma A, Tiwari S, Singh V, Singh DK, et al. Synthesis and evaluation of small libraries of triazolylmethoxy chalcones, flavanones and 2-aminopyrimidines as inhibitors of my-cobacterial FAS-II and PknG. Bioorg Med Chem 2012; 20: 5150-63
71. Guantai EM, Ncokazi K, Egan TJ, Gut J, Rosenthal PJ, Smith PJ, et al. Design, synthesis and in vitro antimalarial evaluation of triazole-linked chalcone and dienone hybrid compounds. Bioorg Med Chem 2010; 18: 8243-56
72. Schobert R, Biersack B, Dietrich A, Knauer S, Zoldakova M, Frue-hauf A, et al. Pt(II) complexes of a combretastatin A-4 analogous chalcone: Effects of conjugation on cytotoxicity, tumor specificity, and long-term tumor growth suppression. J Med Chem 2009; 52(2): 241-6
73. Via DL, Gia O, Chiarelotto G, Ferlin MG. DNA-targeting pyrroloquinoline-linked butenone and chalcones: Synthesis and biological evaluation. Eur J Med Chem 2009; 44(7): 2854-61
74. Kamal A, Shankaraiah N, Prabhakar S, Reddy CR, Markandeya N, Reddy KL, et al. Solid-phase synthesis of new pyrrolobenzodiazepine-chalcone conjugates: DNA-binding affinity and anticancer activity. Bioorg Med Chem Lett 2008; 18(7): 2434-9
75. Kamal A, Prabhakar S, Janaki Ramaiah M, Venkat Reddy P, Ratna Reddy C, Mallareddy A, et al. Synthesis and anticancer activity of chalcone-pyrrolobenzodiazepine conjugates linked via 1,2,3-triazole ring side-armed with alkane spacers. Eur J Med Chem 2011; 46(9): 3820-31
76. Kamal A, Ramakrishna G, Raju P, Viswanath A, Ramaiah MJ, Balakishan G, et al. Synthesis and anti-cancer activity of chalcone linked imidazolones. Bioorg Med ChemLett 2010; 20(16): 4865-9
77. Ramaiah MJ, Pushpavalli S, Krishna GR, Sarma P, Mukhopadhyay D, Kamal A, et al. Chalcone-imidazolone conjugates induce apoptosis through DNA damage pathway by affecting telomeres. Cancer Cell Int 2011; 11: 11 (1-12)
78. Kamal A, Mallareddy A, Suresh P, Shaik TB, Lakshma Nayak V, Kishor C, et al. Synthesis of chalcone-amidobenzothiazole conjugates as antimitotic and apoptotic inducing agents. Bioorg Med Chem 2012; 20(11): 3480-92
79. Yang X, Wang W, Tan J, Song D, Li M, Liu D, et al. Synthesis of a series of novel dihydroartemisinin derivatives containing a substituted chalcone with greater cytotoxic effects in leukemia cells. Bioorg Med Chem Lett 2009; 19(15): 4385-8
80. Mourad MA, Abdel-Aziz M, Abuo-Rahma Gel D, Farag HH. Design, synthesis and anticancer activity of nitric oxide donating/chalcone hybrids. Eur J Med Chem 2012; 54: 907-13
81. Ruan BF, Lu X, Tang JF, Wei Y, Wang XL, Zhang YB, et al. Synthesis, biological evaluation, and molecular docking studies of resveratrol derivatives possessing chalcone moiety as potential antitubulin agents. Bioorg Med Chem 2011; 19(8): 2688-95
82. Gu X, Ren Z, Tang X, Peng H, Ma Y, Lai Y, et al. Synthesis and biological evaluation of bifendate-chalcone hybrids as a new class of potential P-glycoprotein inhibitors. Bioorg Med Chem 2012; 20(8): 2540-8
83. Abdel-Aziz M, Park SE, Abuo-Rahma Gel D, Sayed MA, Kwon Y. Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: Synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity. Eur J Med Chem 2013; 69: 427-38
84. Singh P, Raj R, Kumar V, Mahajan MP, Bedi PM, Kaur T, et al. 1,2,3-Triazole tethered beta-lactam-chalconebifunctional hybrids: Synthesis and anticancer evaluation. Eur J Med Chem 2012; 47(1): 594-600
85. Rose, S.D., Hartman, R.F. Modified chalcone compounds as antimitotic agents. WO2007133588 (2007)
86. Potter, G.A., Butler, P.C. 3,4-Methylenedioxy-substituted chalcones as therapeutic agents. US007598294 (2009)
87. Lin, C.N., Tu, H.Y., Huang, A.M., Hoar, T.C., Yang, S.C., Pu, Y.S., Chang, J.-G. Synthesis and biological evaluation of 2’,5’-dimethoxychalcone derivatives as microtubule-targeted anticancer agents. US20110306775 (2011)
88. Konieczny, M., Skladanowski, A., Lemke, K., Pieczykolan, J. Novel chalcone derivatives with cytotoxic activity. WO2011009826 (2011)
89. Kamal, A., Prasad, B.R., Reddy, A.M. Chalcone linked pyr-rolo[2,1-C][1,4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof. US20110201600 (2011)
90. Kamal, A., Gadupudi, R., Gorre, B., Paidakula, R., Arutla, V., Moku, B. Imidazolone-chalcone derivatives as potential anticancer agent and process for the preparation thereof. WO2011086412 (2011) & WO2011086412 (2011)
91. Kamal, A., Dudekula, D., Jonnala, S.R., Earla, V.B. Imidazothia-zole-chalcone derivatives as potential anticancer agents and process for the preparation thereof. WO2011045646 (2011) & US20120271054 (2012)
92. Kamal, A., Mallareddy, A., Suresh, P., Shetti, R.V.C.R.N.C., Pal, H.C., Saxena, A.K. Benzothiazole hybrids useful as anticancer agents and process for the preparation thereof. WO2012104875 (2012) & US20140039190 (2014)
93. Ahmed, K., Reddy, A.M., Paidakula, S., Rao, N.S., Shetti, R.V.C.R.N.C. Amidobenzothiazoles and process for the preparation thereof. WO2012104857 (2012)
94. Anderson, G.L., Kaimari, T.A.R. 1-Adamantyl chalcones for the treatment of proliferative disorders. US20110319483 (2011)
95. Van der Westhuizen, J.H., Eljaleel, A.E.M.N., Bonnet, S.L., Wil-helm-Mouton, A. Aminoalkyl substituted chalcones and analogues and derivatives thereof. WO2011151789 (2011)
96. Onoki, H., Tawara, K., Kudo, Y. Composition containing chalcone and isoflavone of Angelica keiskei. JP2011190245 (2011)
97. Park, K.H., Lee, J.W., Ryu, Y.B., Ryu, H.W., Lee, S.-A. Method for screening anticancer compounds inhibiting function of TM4SF5 and anticancer composition containing chalcone compounds. US20120282619 (2012) & CA2671987C (2014)
98. Erker, T., Brunhofer, G., Jager, U., Vanura, K., Dirsch, V., Heib, E. Vinylogouschalcone derivatives and their medical use. WO2012013725 (2012)
99. Chang, Y.T., Lee, S.C., Kang, N.Y. Chalcone structure fluorescence dye for embryonic stem cell probe. WO2012026886 (2012)
100. Chang, S.T., Tung, Y.T. Use of acacia extracts and their compounds on inhibition of xanthine oxidase. US20120009288 (2012)
101. Fiorentino Gomez, S., Cifuentes Barreto, M.C., Hernandez Mon-taño, J.F., Santander Gonzales, S.P., Urueña Pinzon, C.P., Cas-tañeda, U. Bioactive fraction of Petiveria alliacea, pharmaceutical composition containing same and combination with immunostimu-lants for treating cancer. US20120294897 (2012) & US8734863 (2014)
102. Biswal, S., Thimmulappa, R., Kumar, S., Malhotra, S.V., Kumar, V., Jung-Hyun, K. Chalcone derivatives as Nrf2 activators. WO116362 (2012)
103. Sashidhara, K.V., Kumar, A., Kumar, M., Sarkar, J., Sinha, S.K. Coumarin-chalcones as anticancer agents. WO017454 (2012)
104. Chesney, J., Trent, J.O., Telang, S., Clem, B., Meier, J. Family of pfkfb3 inhibitors with anti-neoplastic activities. WO156783 (2008)
105. Carmeliet, P., Quaegebeur, A. Means and methods for the treatment of neurodegenerative disorders. WO2012119949 (2012)
106. Carmeliet, P. Means and methods for the treatment of pathological angiogenesis. WO2013007766 (2013)
107. Wu, Y.C., Chang, F.R., Hsieh, T.J., Du, Y.C. Tsai, Y.H., Hsieh, C.T. Composition for treating diabetics and metabolic diseases and a preparation method thereof. WO2013022951 (2013)